EUCTR2007-002683-10-DE进行中（未招募）不适用
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Reactogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Ambulatory Elderly Adults Aged 68 Years and Older Who Received 1 or More Doses of 23-valent Pneumococcal Polysaccharide Vaccine at Least 3 Years Before Study Enrollment
Wyeth Research Division of Wyeth Pharmaceuticals Inc.0 个研究点目标入组 1,053 人开始时间: 2008年6月13日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 1,053
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Each subject must participate in the informed consent process and sign and date the informed consent form (ICF) before any procedures specified in this protocol are performed.
- •Subjects must meet the following criteria:
- •[1] Male or female adults 68 years of age and older at time of enrollment.
- •[2] Documented vaccination with 1 or more doses of 23vPS at least 3 years before study enrollment.
- •[3] Determined by medical history, physical examination, and clinical judgment to be eligible for the study. Subjects with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease 6 weeks before receipt of study vaccine, are eligible.
- •[4] Able to complete an electronic diary (e-diary) and follow study procedures, in the opinion of the investigator.
- •[5] Expected to be available for the duration of the trial (up to 6 months).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) no
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •[1] History of severe adverse reaction associated with a vaccine.
- •[2] Receipt of any vaccine within 28 days before study vaccination, except influenza vaccine. (See criteria for temporary delay of vaccination.)
- •[3] Vaccination with a diphtheria-containing vaccine within 6 months before test article administration or anticipated receipt before study completion.
- •[4] Documented S pneumoniae infection within the past 5 years.
- •[5] Residence in a nursing home, long-term care facility or other institution, or requirement of semi-skilled nursing care. An ambulatory subject who is a resident of a retirement home or village is eligible for the trial.
- •[6] Evidence of dementia or other severe cognitive impairment based on a Mini-Mental State Examination (MMSE) score of less than or equal to 21.
- •[7] Known or suspected immunodeficiency or receiving treatment with immunosuppressive therapy including cytotoxic agents or systemic corticosteroids, eg, for cancer, HIV, or autoimmune disease. If systemic corticosteroids have been administered short term for treatment of an acute illness, subjects should be excluded from the study until corticosteroid therapy has been discontinued for at least 28 days before test article administration.
- •[8] Serious chronic disorder including metastatic malignancy, severe chronic obstructive pulmonary disease requiring supplemental oxygen, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that in the investigator’s opinion precludes the subject from participating in the study.
- •[9] Poor eyesight or missing eyesight, requiring third-party support to read.
- •[10] Receipt of any blood products, including immunoglobulin, within 6 months before test article administration, or anticipated receipt before study completion.
- •[11] In the opinion of the investigator, unable to receive a vaccination in the deltoid muscle of either arm due to insufficient muscle mass or limitation of arm movement that would interfere with the evaluation of the study objectives.
- •[12] Current anticoagulant therapy or a history of bleeding diathesis that would contraindicate intramuscular (IM) injection. (Note: antiplatelet drugs such as aspirin and clopidogrel are permitted).
- •[13] Intent to receive any other investigational vaccine or agent from 1 month (28 days) before study enrollment until the conclusion of the study.
- •[14] Any medical condition that would, in the opinion of the investigator, interfere with the evaluation of the study objectives.
- •Criteria for Temporary Delay of Vaccination
- •The following conditions are temporary or self-limiting, and a subject may be included in the study once the condition(s) has/have resolved and no other exclusion criteria are met:
- •1. Current febrile illness (oral temperature =38.0°C [100.4°F]) or other acute illness within 48 hours before test article administration.
- •2. Receipt of antibiotic therapy for an acute illness within 72 hours before test article administration.
- •3. Receipt of any inactivated vaccine within 14 days and any live vaccine within 28 days before test article administration.
研究者
相似试验
进行中（未招募）
不适用
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23-valent Pneumococcal Polysaccharide Vaccine - NDPneumococcal InfectionMedDRA version: 12.1Level: LLTClassification code 10061353Term: Pneumococcal infectionEUCTR2009-011396-77-ITWyeth Research Division on Wyeth Pharmaceuticals Inc.200
进行中（未招募）
不适用
A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, and Reactogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Ambulatory Elderly Adults Aged 68 Years and Older Who Received 1 or More Doses of 23-valent Pneumococcal Polysaccharide Vaccine at Least 3 Years Before Study EnrollmentEUCTR2007-002683-10-SEWyeth Research Division of Wyeth Pharmaceuticals Inc.1,053
进行中（未招募）
不适用
Trial of vaccine in HIV patients from 6 years old to olderEUCTR2009-011564-11-Outside-EU/EEAWyeth Pharmaceuticals Inc. (a Pfizer Company)300
进行中（未招募）
1 期
A Phase 3, Open-label, Single-Arm Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 13-valent Pneumococcal Conjugate Vaccine in Children With Sickle Cell Disease Previously Immunized With 23-valent Pneumococcal Polysaccharide VaccinePneumococcal infectionMedDRA version: 9.1Level: LLTClassification code 10061353Term: Pneumococcal infectionEUCTR2009-011396-77-FRWyeth Research Division of Wyeth Pharmaceuticals Inc.158
进行中（未招募）
1 期
Safety, Tolerability and Immunogenicity of 13 valent Pneumococcal Conjugate Vaccine (13vPnC) in children with Sickle Cell Disease from 6 to 18 years of age.EUCTR2009-011396-77-GBWyeth Pharmaceuticals Inc. (a Pfizer Company)158